Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00996723 · ClinicalTrials.gov registry record · Phase 1

Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

A Phase 1 study, sponsored by St. Jude Children's Research Hospital.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target

NCT00996723: Completed Phase 1 study, sponsored by St. Jude Children's Research Hospital.

NCT00996723 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00996723, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).

Interventions

  • DRUG vandetanib and dasatinib

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2009-10
Est. Completion 2014-06
Phase Phase 1

What the finished NCT00996723 record still lists

NCT00996723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 1 intervention - of which vandetanib and dasatinib is the first listed.

NCT00996723 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00996723 about?

NCT00996723 is a clinical study titled "Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)". This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).

What is the current status of trial NCT00996723?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-10. Estimated completion is 2014-06.

What interventions are being tested in trial NCT00996723?

The interventions under investigation include: vandetanib and dasatinib (DRUG).

Who is sponsoring clinical trial NCT00996723?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00996723's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00996723, the US trial registry maintained by the National Library of Medicine. NCT00996723 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.